Outpatient platinum-taxane intraperitoneal chemotherapy regimen for ovarian cancer

International Journal of Gynecological Cancer

Volumn 19, Issue 7, 2009, Pages 1195-1198

  Seamon, Leigh G ^a   Carlson, Matthew J ^a   Richardson, Debra L ^a   Cohn, David E ^a   Fowler, Jeffrey M ^a   Copeland, Larry J ^a   O'Malley, David M ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Docetaxel; Intraperitoneal chemotherapy; Outpatient treatment; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; PLATINUM DERIVATIVE; TAXOID;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; LEUKOPENIA; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; OUTPATIENT CARE; OVARY CANCER; PERITONEUM CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PYELONEPHRITIS; SMALL INTESTINE OBSTRUCTION; THROMBOCYTOPENIA; TINNITUS; TREATMENT RESPONSE; URINARY TRACT INFECTION; UTERINE TUBE CARCINOMA; CYSTADENOCARCINOMA; DRUG ADMINISTRATION; EVALUATION; INTRAPERITONEAL DRUG ADMINISTRATION; MIDDLE AGED; OUTPATIENT; OVARY TUMOR; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CYSTADENOCARCINOMA, SEROUS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, INTRAPERITONEAL; MIDDLE AGED; OUTPATIENTS; OVARIAN NEOPLASMS; PACLITAXEL; PLATINUM COMPOUNDS; RETROSPECTIVE STUDIES; TAXOIDS; TREATMENT OUTCOME;

EID: 73449119325     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181b33d5b     Document Type: Article

References (27)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Hacker NF, Berek JS, Lagasse LD, et al. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol. 1983;61:413-420.
3. Vogl SE, Pagano M, Kaplan BH, et al. Cisplatin based combination chemotherapy for advanced ovarian cancer. High overall response rate with curative potential only in women with small tumor burdens. Cancer. 1983;51:2024-2030.
4. Hoskins WJ. Epithelial ovarian carcinoma: principles of primary surgery. Gynecol Oncol. 1996;55:S91-S96.
5. Makar AP, Baekelandt M, Trope CG, et al. The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol. 1995; 57:175-180.
6. Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248-1259.
7. Allen DG, Heintz AP, Touw FW. A meta-analysis of residual disease and survival in stage III and IV carcinoma of the ovary. Eur J Gynaecol Oncol. 1995;16:349-356.
8. Eisenhauer EL, Abu-Rustum NR, Sonoda Y, et al. The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecol Oncol. 2008;108:276-281.
9. Rubin SC, Hoskins WJ, Saigo PE, et al. Prognostic factors for recurrence following negative second-look laparotomy in ovarian cancer patients treated with platinum-based chemotherapy. Gynecol Oncol. 1991;42:137-141.
10. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34-43.
11. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21:3194-3200.
12. Jaaback K, Johnson N. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev. 2008;CD005340.
13. Gore M, du Bois A, Vergote I. Intraperitoneal chemotherapy in ovarian cancer remains experimental. J Clin Oncol. 2006;24:4528-4530. (Pubitemid 46630945)
14. Markman M. Point: intraperitoneal chemotherapy in the management of ovarian cancer. J Natl Compr Can Netw. 2004;2:549-554.
15. Ozols RF. Challenges for chemotherapy in ovarian cancer. Ann Oncol. 2006;17:v181Yv187.
16. Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2004;96: 1682-1691.
17. Cancer Therapy Evaluation Program. Common Terminology Criteria For Adverse Events, Version 3 (CTCAEv3.0). DCTD, NCI, NIH, DHHS. March 31, 2003. Available at: http://ctep.cancer.gov. Accessed March 26, 2009.
18. Guppy AE, Rustin GJS. CA 125 response: can it replace the traditional response criteria in ovarian cancer? Oncologist. 2002;7:437-443.
19. Burkett AM, Cohn DE, Copeland LJ. Vaginal evisceration during intraperitoneal chemotherapy for advanced ovarian cancer. Gynecol Oncol. 2007;104:491-493.
20. National Cancer Institute Clinical Announcement 01/05/06. Available at: http://ctep.cancer.gov/highlights/ovarian.html. Accessed July 7, 2008.
21. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996;335:1950-1955.
22. Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwest Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19:1001-1007.
23. Ozols RF, Bookman MA, Young RC. Intraperitoneal chemotherapy for ovarian cancer. N Engl J Med. 2006;354:1641-1642.
24. Rao G, Crispens M, Rothenberg ML. Intraperitoneal chemotherapy for ovarian cancer: overview and perspective. J Clin Oncol. 2007;25: 2867-2872.
25. Zylbergerg B, Ravina JH, Salat-Baroux J, et al. Polychemotherapy of ovarian cancer via combined intravenous and intraperitoneal routes. Technique and preliminary results. J Gynecol Obstet Biol Reprod. 1986;15:671-676.
26. Gadducci A, Carnino F, Chiara S. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest. Gynecol Oncol. 2000;76:157-162.
27. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology Myeloid Growth Factors V.I.2009. Available at: http://www.nccn.org/ professionals/physician-gls/PDF/myeloid-growth.pdf. Accessed March 26, 2009.